Datamonitor's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.
Datamonitors' Pronova BioPharma Norge AS Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Pronova BioPharma Norge AS since January 2007.
– Provides intelligence on Pronova BioPharma Norge AS's M&A, strategic partnerships and alliances, capital raising and private equity transactions. – Detailed reports of various financial transactions undertaken by Pronova BioPharma Norge AS and its subsidiaries since 2007. – Information about key financial and legal advisors for Pronova BioPharma Norge AS's financial deals transactions. – Financial deals tables and charts covering deal value and volumes trend, deal types and geography-based deal activity.
This report includes Pronova BioPharma Norge AS's contact information and business summary, tables, graphs, a list of partners and targets, a breakdown of financial and legal advisors, deal types, top deals by deal value, detailed deal reports, and descriptions and contact details of the partner, target, investor, and vendor firms, where disclosed.
The profile also includes detailed deal reports for all M&A, private equity, public offering, venture financing, partnership and divestment transactions undertaken by Pronova BioPharma Norge AS. These deal reports contain information about target company financials, sources of financing, method of payment, deal values, and advisors for various parties, where disclosed.
Reasons to Purchase:
– Access comprehensive financial deals data along with charts and graph covering M&A, private equity, and partnerships and alliances. – Form an independent opinion about Pronova BioPharma Norge AS’s growth strategies through the organic and inorganic activities undertaken since 2007. – Track your competitors’ business structure and growth strategies.
Our reports have been used by over 10K customers, including:
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H1 2019 Summary Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR...
The Global Cancer Monoclonal Antibody Partnering 2014-2019: Deal trends, players, financials and forecasts report provides an understanding and access to the cancer monoclonal antibody partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in cancer monoclonal antibody partnering...
Angiopoietin 1 Receptor (Endothelial Tyrosine Kinase or Tunica Interna Endothelial Cell Kinase or Tyrosine Kinase With Ig And EGF Homology Domains 2 or Tyrosine Protein Kinase Receptor TEK or Tyrosine Protein Kinase Receptor TIE 2 or p140 TEK or CD202b or TIE2 or TEK or EC 188.8.131.52) - Pipeline Review, H1 2019 Summary According...
Pharmaceutical Analytical Testing Outsourcing Market Size, Share & Trends Analysis Report By Service (Bioanalytical, Stability Testing, Method Development & Validation), And Segment Forecasts, 2019 - 2026 The global pharmaceutical analytical testing outsourcing market size is projected to reach USD 10.4 billion by 2026...